Bernstein raises target for Johnson & Johnson stock from USD 261 to USD 270

Published on 10/19/2026 at 09:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter sales reached USD 25.4 billion on October 13, 2026. Johnson & Johnson stock costs EUR 227.00 on October 19, 2026, 0.55 percent below Xetra.

Analyst targets and operating scale

Bernstein raised its Johnson & Johnson target from USD 261 to USD 270 on October 15, 2026.
Third-quarter 2026 sales reached USD 25.4 billion, up 5.9 percent year over year.
Johnson & Johnson stock trades at EUR 227.00 at 9:14 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.55 percent below the Xetra close of October 16, 2026.

Nahaufnahme von weißen Tabletten und Kapseln auf glatter Oberfläche — Makroaufnahme weißer Tabletten und Kapseln illustriert Produktpalette von Johnson & Johnson, ISIN US4781601046, im Detail, Illustration mit AI erstellt.

Bernstein raised its Johnson & Johnson target from USD 261 to USD 270 while keeping a Market Perform rating on October 15, 2026, according to Investing.com. The move gives investors a fresh valuation reference after the company's third-quarter update.

Three October events reset expectations

On October 13, 2026, Johnson & Johnson reported third-quarter sales of USD 25.4 billion, up 5.9 percent from USD 24.0 billion a year earlier, and lifted its adjusted earnings per share midpoint to USD 11.10 for fiscal year 2026, according to Johnson & Johnson. On October 14, RBC Capital cut its target from USD 290 to USD 280 while keeping an Outperform rating, as reported by Markets Insider. Bernstein's October 15 target increase was the latest of the three dated valuation changes.

What does MedTech mean for growth?

The segment split is the key counterweight to the higher guidance. Innovative Medicine generated USD 16.8 billion of third-quarter 2026 sales and 7.9 percent operational growth, while MedTech produced USD 8.6 billion and 2.5 percent growth, according to the company release. The figures show why pharmaceutical execution is carrying more of the growth burden than medical technology.

Two dates matter for shareholders

Johnson & Johnson declared a fourth-quarter 2026 cash dividend of USD 1.34 per share on October 13, 2026. The ex-dividend date is November 24, 2026, and payment is scheduled for December 8, 2026, according to Johnson & Johnson. The company also plans an enterprise business review on December 8, 2026, where it is expected to discuss its 2027 outlook and the potential Orthopaedics separation.

Stock stays below the Xetra close

The valuation signals are mixed: Bernstein moved its target higher, while RBC lowered its target one day earlier. That contrast puts greater emphasis on whether MedTech growth improves alongside the company's pharmaceutical momentum.

Johnson & Johnson stock was trading at EUR 227.00 at Lang & Schwarz on October 19, 2026 at 9:14 a.m. CEST, 0.55 percent below the Xetra close of October 16, 2026 (EUR 228.25). The company trades on the NYSE under ticker JNJ, according to the October 13 release. The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.